Rep. David Taylor Buys Medpace Holdings, Inc. (NASDAQ:MEDP) Shares

Representative David Taylor (Republican-Ohio) recently bought shares of Medpace Holdings, Inc. (NASDAQ:MEDP). In a filing disclosed on May 28th, the Representative disclosed that they had bought between $1,001 and $15,000 in Medpace stock on May 15th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 5/15/2026.
• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 5/15/2026.
• Purchased $1,001 – $15,000 in shares of AT&T (NYSE:T) on 5/15/2026.
• Sold $15,001 – $50,000 in shares of Alphabet (NASDAQ:GOOGL) on 5/15/2026.
• Purchased $1,001 – $15,000 in shares of Parker-Hannifin (NYSE:PH) on 5/15/2026.
• Sold $1,001 – $15,000 in shares of Apple (NASDAQ:AAPL) on 5/15/2026.
• Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 4/27/2026.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 4/27/2026.
• Purchased $1,001 – $15,000 in shares of Progressive (NYSE:PGR) on 4/27/2026.
• Sold $1,001 – $15,000 in shares of Lam Research (NASDAQ:LRCX) on 4/27/2026.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $447.11 on Friday. The business’s 50 day simple moving average is $457.47 and its two-hundred day simple moving average is $513.97. The firm has a market cap of $12.77 billion, a P/E ratio of 28.10, a PEG ratio of 2.27 and a beta of 1.19. Medpace Holdings, Inc. has a 52-week low of $291.28 and a 52-week high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.74 by $0.54. The business had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The company’s quarterly revenue was up 26.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities analysts forecast that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the sale, the president directly owned 15,000 shares of the company’s stock, valued at $6,829,500. This trade represents a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 20.50% of the stock is owned by corporate insiders.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Bronstein, Gewirtz & Grossman, Faruqi & Faruqi, The Gross Law Firm, Rosen, Schall, Pomerantz, and others, issued updates this week about a pending class-action lawsuit against Medpace and reminded shareholders of upcoming lead-plaintiff deadlines, keeping legal risk in focus for the stock. Article Title
• Neutral Sentiment: The latest notices do not add new operational or financial guidance from Medpace; they mainly reiterate the same securities-fraud allegations and court deadline, so the immediate market impact is likely driven more by headline risk than by fundamentals. Article Title
• Neutral Sentiment: Short-interest data released alongside the legal headlines showed no meaningful borrowable shares reported, suggesting the move in MEDP is being driven by news flow rather than a clear short-selling signal.

Institutional Trading of Medpace

Institutional investors and hedge funds have recently modified their holdings of the business. Cibc World Market Inc. purchased a new stake in shares of Medpace during the third quarter valued at approximately $5,033,000. Capital Fund Management S.A. increased its position in shares of Medpace by 129.5% during the third quarter. Capital Fund Management S.A. now owns 32,412 shares of the company’s stock valued at $16,665,000 after acquiring an additional 18,287 shares during the last quarter. Dorsey Wright & Associates purchased a new stake in shares of Medpace during the third quarter valued at approximately $5,082,000. Victory Capital Management Inc. increased its position in Medpace by 32.9% in the third quarter. Victory Capital Management Inc. now owns 30,539 shares of the company’s stock worth $15,702,000 after buying an additional 7,565 shares during the last quarter. Finally, Intech Investment Management LLC increased its position in Medpace by 31.9% in the third quarter. Intech Investment Management LLC now owns 18,395 shares of the company’s stock worth $9,458,000 after buying an additional 4,448 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

MEDP has been the subject of several analyst reports. TD Cowen raised Medpace from a “sell” rating to a “hold” rating and lowered their price objective for the stock from $462.00 to $419.00 in a research note on Wednesday, February 18th. Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective for the company in a research note on Friday, February 13th. Finally, BMO Capital Markets lowered their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research note on Friday, April 24th. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Medpace has an average rating of “Hold” and an average target price of $467.08.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.